Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ FDA faces intense criticism narrows use of controversial Alzheimer’s drug for patients with early disease

FDA faces intense criticism narrows use of controversial Alzheimer’s drug for patients with early disease



But in a news briefing earlier this month after the drug was approved, Peter Stein, director of the FDA’s Office of New Drugs, said, “It is not expected that this will only necessarily be relevant in the early stages because amyloid is an important part, is a hallmark of the disease throughout the course. The expectation is that this drug will provide benefits across this spectrum. ”


Source link